Accesswire
06 Oct 2025, 13:00 UTC · 50w ago
Verdict
Headline leans bullish. We score JAGX +0.80 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Following a Type C meeting, Jaguar Health assessed that its ongoing MVID study may potentially support approval for crofelemer without requiring new trials.
So whatA viable regulatory pathway to approval for an ultra-rare disease with no approved treatments dramatically improves the commercial prospects and valuation of the asset.
More positive than 98% of claims this week
Reinitiated crofelemer dosing in a UAE MVID trial patient demonstrated a 37% reduction in parenteral support, improving from a 27% reduction at 12 weeks.
Continue reading
5 related stories
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 93% of claims this week
The company will make selected amendments to its clinical study based on FDA advice before continuing interactions to finalize the development pathway.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reported a productive meeting with the FDA regarding a development pathway for MVID and positive results from a proof-of-concept trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
−99.4%
Price is moving against the score
$7.06 vs $1149.75 close before publication (Oct 3) · not market-adjusted
JAGX chart →
